Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Axogen (AXGN) Short-Term Debt repayments (2017 - 2018)

Axogen's quarterly Short-Term Debt repayments came in at $14.3 million in Q2 2018, down 4.61% year-on-year from $15.0 million in Q2 2017, and down 11.37% quarter-over-quarter from $16.2 million in Q1 2018.

Axogen has reported Short-Term Debt repayments for 2 years, with the latest figure at $14.3 million in Q2 2018.

  • For the quarter ending Q2 2018, Short-Term Debt repayments fell 4.61% year-over-year to $14.3 million; the trailing twelve-month figure through Dec 2018 stood at $30.5 million (down 47.09% YoY), and the FY2018 full-year result was $30.5 million, down 47.09% from the prior year.
  • Short-Term Debt repayments for Q2 2018 stood at $14.3 million, down from $16.2 million in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $16.2 million in Q1 2018, with the low at $11.3 million in Q1 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 259.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Axogen 2.00 Bn 1.90 Bn 46.19 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2018 14.33 Mn
Jun 30, 2018 14.33 Mn
Mar 31, 2018 16.16 Mn
Mar 31, 2018 16.16 Mn
Dec 31, 2017 16.05 Mn
Dec 31, 2017 16.05 Mn
Sep 30, 2017 15.26 Mn
Sep 30, 2017 15.26 Mn
Jun 30, 2017 15.02 Mn
Jun 30, 2017 15.02 Mn
Mar 31, 2017 11.30 Mn
Mar 31, 2017 11.30 Mn